Phase II Trial of Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Summary
The purpose of this study is to determine the safety and efficacy of nivolumab, albumin-bound paclitaxel, paricalcitol, cisplatin, and gemcitabine when given together treat advanced pancreatic cancer.
General Information
NCT#: NCT02754726
Study ID: NAPPCG-EB 2015-001
Trial Phase: Phase II
Trial Sponsor: Translational Genomics Research Institute (TGen), HonorHealth Research Institute, Lustgarten Foundation
Therapies Used in This Trial: Nab-paclitaxel, Gemcitabine, Cisplatin, Nivolumab, Paricalcitol